What is Mouse Specifics?
Mouse Specifics operates at the intersection of biotechnology and advanced instrumentation, providing specialized tools for the physiological study of human disease models. The company is best known for its proprietary platforms, including DigiGait for automated gait analysis and ECGenie for non-invasive electrocardiogram recording. These solutions are engineered to improve the reproducibility and translatability of pre-clinical data, addressing a significant pain point in drug discovery and disease modeling. By prioritizing non-invasive methodologies, Mouse Specifics not only improves the quality of research outcomes but also aligns with modern standards for laboratory animal welfare, positioning itself as an essential partner for academic and pharmaceutical research institutions globally.
How much funding has Mouse Specifics raised?
Mouse Specifics has raised a total of $51K across 1 funding round:
Debt
$51K
Debt (2021): $51K with participation from PPP
Key Investors in Mouse Specifics
PPP
Public-Private Partnership
What's next for Mouse Specifics?
With the infusion of $51K, Mouse Specifics is expected to focus on the commercial scaling of its product portfolio and the potential development of next-generation diagnostic sensors. The current Series B/C stage indicates a transition from product-market fit to aggressive market penetration. Strategic priorities likely include expanding the global distribution network for its core instrumentation and investing in R&D to broaden the scope of its physiological monitoring capabilities. As the demand for high-fidelity, translatable data in pre-clinical trials continues to rise, the company is poised to capture a larger share of the life sciences instrumentation market, leveraging its established reputation for precision and ethical research practices to drive long-term value.
See full Mouse Specifics company page
